8-K: MindMed Announces Positive Phase 2b Trial Results for MM120 in Generalized Anxiety Disorder

MindMed's MM120 demonstrated significant and durable improvement in Generalized Anxiety Disorder symptoms in a Phase 2b trial, with a 7.7-point improvement over placebo at 12 weeks.

Summary

• MindMed announced positive topline results from its Phase 2b trial of MM120 for Generalized Anxiety Disorder (GAD).
• The trial met its primary and all secondary endpoints with statistical significance.
• A 7.7-point improvement over placebo was observed in the Hamilton Anxiety Scale (HAM-A) score at week 12, with a p-value of 0.003.
• The study showed a 48% clinical remission rate at week 12.
• MM120 demonstrated a rapid onset of action, with a 1.8-point reduction in CGI-S within 24 hours.
• The effect size of 0.81 at 12 weeks is more than double the standard of care for existing treatments.
• A pharmacokinetic (PK) bridging study showed that the orally dissolving tablet (ODT) formulation of MM120 has a 50% faster onset of action, 17% improved bioavailability, and a 23% increase in AUC at target concentration compared to the capsule formulation.
• The company's cash and cash equivalents of $99.7 million as of December 31, 2023, and a committed credit facility are expected to fund operations into 2026.

Sentiment

Score: 9

Explanation: The document presents very positive results from the Phase 2b trial, with strong efficacy and a favorable safety profile. The Breakthrough Therapy Designation and enhanced product profile of the ODT formulation further boost the positive sentiment. The company's cash runway into 2026 also provides financial stability.

Positives

• MM120 demonstrated a statistically significant and clinically meaningful improvement in GAD symptoms.
• The drug showed a rapid onset of action and durable effects.
• The ODT formulation of MM120 has an enhanced pharmacokinetic profile.
• The Breakthrough Therapy Designation from the FDA provides potential for accelerated development and review.
• The company has a strong cash position to fund operations into 2026.
• The trial showed a favorable tolerability profile with mostly mild to moderate adverse events.
• There were no drug-related serious adverse events or suicide-related safety signals.

Negatives

• The study did report some adverse events, though mostly mild to moderate, including illusion, nausea, headache, and visual hallucinations.
• Some participants discontinued the study early, though the completion rate was consistent with other studies in the drug class.

Risks

• The company is still in the clinical trial phase and needs to obtain regulatory approvals before commercialization.
• The development of psychedelic-inspired medicines is subject to regulatory scrutiny and uncertainty.
• The company has a history of negative cash flows and may need to raise additional capital.
• The market for psychedelic medicines is novel and carries inherent risks.
• There are risks associated with clinical trials, including the possibility of not achieving desired outcomes or regulatory approvals.

Future Outlook

MindMed plans to initiate two Phase 3 pivotal clinical trials for MM120 in GAD in the second half of 2024, with a 12-week randomized, placebo-controlled primary efficacy study design and an open-label extension to establish retreatment parameters. The company also plans to evaluate additional clinical indications for MM120.

Management Comments

• Robert Barrow, CEO, stated that the company aims to be a global leader in brain health.
• Robert Barrow noted that the company's pipeline is diversified and targets significant unmet medical needs.
• Management believes the Phase 2b data supports the advancement of 100 g MM120 into Phase 3 development for GAD.

Industry Context

The results are significant in the context of the growing need for new treatments for mental health disorders, particularly GAD, where current treatments often have limited efficacy or undesirable side effects. The company is leveraging the established interventional psychiatry model used by Spravato, which could facilitate the commercialization of MM120.

Comparison to Industry Standards

• The effect size of 0.81 observed in the MM120 trial is more than double the effect sizes typically seen with standard treatments for GAD, such as benzodiazepines (0.38), SSRIs (0.36), and buspirone (0.17).
• The rapid onset of action and durable effects of MM120 are also notable compared to existing treatments, which often require weeks to show efficacy.
• The company is using the Spravato model for delivery, which has over 3,500 certified delivery clinics, and established reimbursement pathways.
• The company is positioning MM120 as a potential alternative to Spravato, with the potential for fewer treatment sessions and less time spent in treatment per year.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the potential for a new treatment for GAD.
• Patients with GAD may benefit from a new treatment option with improved efficacy and tolerability.
• Healthcare providers may have a new tool to treat GAD, with the potential for better patient outcomes.
• Payers may be interested in a treatment that could reduce healthcare utilization and costs.

Next Steps

• The company plans to initiate two Phase 3 pivotal clinical trials for MM120 in GAD in the second half of 2024.
• The company will have an End-of-Phase-2 meeting with the FDA.
• The company will evaluate additional clinical indications for MM120.
• The company will present full data at a scientific meeting.

Key Dates

Keywords

MM120, Generalized Anxiety Disorder, GAD, Lysergide, Clinical Trial, Phase 2b, Breakthrough Therapy Designation, Pharmacokinetics, ODT, Mental Health, Anxiety, Neuro-pharmaceuticals